cc:

ANIENDINE THE BETTER (CHARLE ELECT)						Docket No. 02940182AA	
		g Date y 21, 2002		Examiner Bahar		Group Art-Unit	
AND OTHER ALE	ANCEMENT OF THE HTANESPILFONAMID		EFFICAC	Y OF LOCAL A	NESTHE	RECEIVED	
☐ Small Ent	· Fi		fied applic	ation.	27 by a v	TECH CENTER 1600/290 erified statement	
☐ A verified	statement to establish			7 FR 1.27 is end	closed.	,	
The fee has been	calculated and is trans						
CLAIMS AS AMENDED						ADDITIONAL	
	CLAIMS REMAINING	HIGHEST # PREV. PAID FOR		IMBER EXTRA	RATE		
TOTAL CLAIMS	AFTER AMENDMENT  18 -	20 =		0	x \$9	.00 \$0.00	
INDEP. CLAIMS	3 -	3 =	:	0	x \$43	3.00 \$0.00	
Multiple Dependent Claims (check if applicable) □						\$0.00	
		TOTAL ADDITIO	NAL FEE	FOR THIS AMI	ENDMEN	T \$0.00	
Please ch A check i The Direct communi Any Any Ruth Tyler-Cros	onal fee is required for a narge Deposit Account in the amount of ctor is hereby authorize additional filing fees repatent application process	No. to cover the d to charge paym rpayment to Dep	e filing fee ent of the osit Accou C.F.R. 1.16 r 37 CFR	int No. 50-204  5. 1.17.  : December 30	, 2003		
				on first class m Commission 22313-1450.	ail under 37 er for Paten ature of Per	ument and fee is being deposited with the U.S. Postal Service as C.F.R. 1.8 and is addressed to the its, P.O. Box 1450, Alexandria, VA	

Typed or Printed Name of Person Mailing Correspondence



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

In repatent application of

Smith

For:

Serial No.: 10/078,658

Group Art Unit: 1617

TECH CENTER 1600/2900

Filed: 02/21/2002

Examiner: Bahar

"ENHANCEMENT OF THE POTENCY AND EFFICACY OF LOCAL

ANESTHETICS WITH IBUTILIDE AND OTHER METHANESULFONAMIDE

DRUGS"

Mail Stop Non-Fee Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## REQUEST FOR RECONSIDERATION UNDER 37 C.F.R. §1.112

Sir:

In response to the Office Action mailed 10/03, 2003, please reconsider the aboveidentified patent application.

Amendments to the Claims are indicated by the notation "original" or "withdrawn" in the listing of claims beginning on page 2 of this paper.

Remarks begin on page 5 of this paper.